Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MLLT3
REST API REST API
Homo sapiens
MLLT3 is differentially expressed in 319 experiments: 133 organism parts: bone marrow, brain, ... (131 more);, 184 disease states: normal, control, ... (182 more);, 101 cell types 364 cell lines 40 compound treatments and 79 other conditions.
Synonyms AF9, YEATS3, AF-9
Orthologs Mllt3 (Mus musculus)   MLLT3 (Gallus gallus)   Mllt3 (Rattus norvegicus)   mllt3 (Danio rerio)   MLLT3 (Bos taurus)   ENSCING00000006124 (Ciona intestinalis)   ear (Drosophila melanogaster)   mllt3 (Xenopus laevis)   MLLT3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term segment specification, protein binding, regulation of transcription, DNA-dependent, nucleus, anterior/posterior pattern specification
InterPro Term YEATS
UniProt Accession Q6LEQ8, B1APT6, B1APT5, B7Z755, B7Z4N5, P42568
Search EB-eye ENSG00000171843
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-3526, E-MTAB-62, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
BT474
3
E-MEXP-440, E-MTAB-37, E-MTAB-62
HepG2
2
E-GEOD-21154, E-GEOD-7307
A549
2
E-GEOD-6013, E-GEOD-3202
BT-474
2
E-GEOD-5823, E-GEOD-3529
DU145
2
E-GEOD-17482, E-GEOD-20089
358 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-MEXP-120, E-MEXP-750, E-GEOD-20677, ... (49 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-18147, E-GEOD-18265, E-GEOD-20033
CD34+
2
E-TABM-145, E-AFMX-5
CD8+ T cell
1
2
E-TABM-145, E-AFMX-5, E-GEOD-6740
CD4+ T cell
1
2
E-GEOD-16190, E-MEXP-1600, E-GEOD-6740
CD33+ myeloid
1
E-AFMX-5
iPSC derived from hASC using minicircle reprogramming vector
1
E-GEOD-20033
95 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-MEXP-2280, E-GEOD-16363, ... (63 experiments)

Factor Value U/D Experiments
multiple myeloma
3
E-MTAB-62, E-GEOD-6691, E-GEOD-2113
hepatocellular carcinoma
2
E-MTAB-62, E-MTAB-37
leiomyosarcoma
2
E-MTAB-62, E-MTAB-37
myxoid liposarcoma
2
E-MTAB-62, E-GEOD-6481
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
colon carcinoma
2
E-GEOD-3726, E-MTAB-62
178 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-697, ... (27 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-GEOD-3720, E-MEXP-1958
Cxcl12
1
E-GEOD-7307
TNF
1
E-GEOD-15205
BCR/ABL1
1
E-GEOD-15811
unknown
1
E-GEOD-7307
cigarette smoke
1
E-TABM-127
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-860, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-19018, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (10 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21138, E-GEOD-21887 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-2117, E-GEOD-13073, E-GEOD-5681, E-MEXP-2657, E-TABM-127, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-16194, E-TABM-276, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-MEXP-1412, E-GEOD-1460, ... (7 experiments)

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276, E-GEOD-2748

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.287 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM